Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2019 May 31;5(6):FSO390.
doi: 10.2144/fsoa-2019-0024.

Extrachromosomal circular DNAs: an extra piece of evidence to depict tumor heterogeneity

Ishita Tandon  1 , Roshni Pal  1 , Jayanta K Pal  1 , Nilesh K Sharma  1
Affiliations
Review

Extrachromosomal circular DNAs: an extra piece of evidence to depict tumor heterogeneity

Ishita Tandon et al. Future Sci OA. .

Abstract

The tumor microenvironment (TME) comprises a heterogeneous number and type of cellular and noncellular components that vary in the context of molecular, genomic and epigenomic levels. The genotypic diversity and plasticity within cancer cells are known to be affected by genomic instability and genome alterations. Besides genomic instability within the chromosomal linear DNA, an extra factor appears in the form of extrachromosomal circular DNAs (eccDNAs; 2-20 kbp) and microDNAs (200-400 bp). This extra heterogeneity within cancer cells in the form of an abundance of eccDNAs adds another dimension to the expression of procancer players, such as oncoproteins, acting as a driver for cancer cell survival and proliferation. This article reviews research into eccDNAs centering around cancer plasticity and hallmarks, and discusses these facts in light of therapeutics and biomarker development.

Keywords: DNA repair; biomarker; eccDNAs; epigenome; neoplasms; tumor heterogeneity; tumor microenvironment.

PubMed Disclaimer

Conflict of interest statement

Financial & competing interests disclosure The authors have no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties. No writing assistance was utilized in the production of this manuscript.

Figures

Figure 1.
Figure 1.. Tumor hallmarks.
The updated tumor hallmarks that define the true nature of complexity and heterogeneity of a tumor, encompassing deregulations at various levels including molecular, genetic, epigenetic, eccDNAs, microDNAs, secreted microDNAs and noncoding miRNAs and environmental pressure. CAR-T: Chimeric antigen receptor-T cell therapy; GOF: Gain of function; LOF: Loss of function; OXPHOS: Oxidative phosphorylation.
Figure 2.
Figure 2.. Extrachromosomal circular DNAs: origin, mechanisms and use as potential cancer biomarkers and therapeutic agents.
Various factors in the form of stress, carcinogens, the DNA repair system, and normal cellular process such as DNA replication and epigenetic processes that contribute to the eccDNA heterogeneity within a tumor, are depicted. Potential cancer therapeutic avenues in the form of gene therapy, small RNA mimetics and inhibitors of DNA repair system are also highlighted. eccDNA: Extrachromosomal DNA; ECF: Extracytoplasmic function; HR: Homologous recombination; MMR: Mismatch repair; NHEJ: Nonhomologous end joining.
See this image and copyright information in PMC

References

    1. Shibue T, Weinberg RA. EMT, CSCs, and drug resistance: the mechanistic link and clinical implications. Nat. Rev. Clin. Oncol. 14(10), 611–629 (2017). - PMC - PubMed
    1. Di J, Yang H, Jiang B, Wang Z, Ji J, Su X. Whole exome sequencing reveals intertumor heterogeneity and distinct genetic origins of sporadic synchronous colorectal cancer. Int. J. Cancer 142(5), 927–939 (2018). - PubMed
    1. Nilendu P, Sarode SC, Tandon Iet al.Mutual concessions and compromises between stromal cells and cancer cells: driving tumor development and drug resistance. Cell. Oncol. (Dordr.) 41(4), 353–367 (2018). - PubMed
    1. Turner KM, Deshpande V, Beyter Det al.Extrachromosomal oncogene amplification drives tumour evolution and genetic heterogeneity. Nature 543(7643), 122–125 (2017). - PMC - PubMed
    1. Albrengues J, Shields MA, Ng Det al.Neutrophil extracellular traps produced during inflammation awaken dormant cancer cells in mice. Science 361(6409), eaao4227 (2018). - PMC - PubMed

LinkOut - more resources